Beam Therapeutics Inc (BEAM) financials
Beam Therapeutics revenue and earnings by year
Beam Therapeutics's revenue was $140 million in the fiscal year to December 31, 2025, up 120.0% from the year before. Net income was -$80.0 million, -57.2% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 344.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 140 | 64 | 378 | 61 | 52 | 0 | 0 |
| Revenue growth | 120.0% | -83.2% | 520.0% | 17.5% | 215916.7% | 33.3% | — |
| Operating income | -384 | -416 | -176 | -338 | -392 | -133 | -75 |
| Operating margin | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | -553166.7% | -417522.2% |
| Net income | -80 | -377 | -133 | -289 | -371 | -195 | -78 |
| Net margin | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435144.4% |
| Diluted EPS | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | — | — |
| Free cash flow | -360 | -356 | -183 | -26 | -113 | -112 | -85 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BEAM in Markets.
See also: BEAM returns
No forecast, no recommendation. This page describes Beam Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.